v3.26.1
Segment Information - Schedule of Reconciliation of the Company's Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Total research and development expenses $ 39,197   $ 24,309   $ 72,667 $ 49,273
General and administrative 9,806   7,143   18,334 14,029
Interest and other income, net (3,445)   (3,354)   (6,138) (7,057)
Net loss (45,558) $ (39,305) (28,098) $ (28,147) (84,863) (56,245)
CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses 39,197   24,309   72,667 49,273
General and administrative [1] 9,806   7,143   18,334 14,029
Interest and other income, net (3,445)   (3,354)   (6,138) (7,057)
Net loss (45,558)   (28,098)   (84,863) (56,245)
Dabogratinib LG-UTUC | CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses 2,512   0   4,952 0
Dabogratinib IR NMIBC | CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses 5,397   2,436   10,645 3,725
Dabogratinib ACH | CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses 6,577   2,588   10,886 6,175
Dabogratinib mUC | CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses 1,270   1,993   2,884 5,248
TYRA-430 HCC | CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses 2,147   2,142   4,193 4,436
TYRA-200 ICC | CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses 661   1,329   1,671 2,794
FGFR Discovery [Member] | CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses 2,486   3,311   5,018 6,443
Other Development Programs [Member] | CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses 1,013   457   1,862 971
Personnel Costs [Member] | CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses [2] 15,205   8,660   26,994 16,683
Facilities And Other Costs [Member] | CODM [Member]            
Segment Reporting [Line Items]            
Total research and development expenses [3] $ 1,929   $ 1,393   $ 3,562 $ 2,798
[1] General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.
[2] Personnel costs include $5.8 million and $3.7 million of stock-based compensation for the three months ended June 30, 2026 and 2025, respectively, and $10.3 million and $7.4 million of stock-based compensation for the six months ended June 30, 2026 and 2025, respectively.
[3] Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.